ArticleThoracic cancer2025
Inherent PD-L1 22C3 Expression in Alveolar Macrophages Impacts the Combined Positive Score Status in Breast Cancer With Pulmonary Metastasis.
Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to determine the impact of inherent programmed death-ligand 1 (PD-L1)-expressing alveolar macrophages (AMs) on the combined positive score (CPS) of PD-L1 (22C3) in metastatic breast cancer in the lungs.
methodsA total of 87 patients with pulmonary metastases of breast cancer were included in this study. Immunohistochemical staining of various PD-L1 antibodies was performed. The CPSs and CPSs excluding the number of PD-L1 positive AMs [CPS(NAM)s] with PD-L1 (22C3) were determined and compared.
resultsAmong 87 enrolled patients, 22 had luminal A breast cancer, 24 had luminal B breast cancer, 13 had HER-2-positive breast cancer, and 28 had triple-negative breast cancer (TNBC). CPSs ≥ 10 was observed only in luminal B (12.5%) and TNBC (35.7%) subtypes (p < 0.001), whereas CPS(NAM)s ≥ 10 was observed only in TNBC (14.3%) (p = 0.011). Changes from the CPS-positive to the CPS(NAM)-negative status occurred in nine cases (10.3%), with significantly higher proportions being observed in the luminal B (12.5%) and TNBC (21.4%) subtypes (p = 0.007). Tumors showing changes from the CPS-positive to the CPS(NAM)-negative status were larger (p < 0.001); similar findings were observed in the TNBC subgroup (p = 0.001).
conclusionThe inclusion of PD-L1 expressing AMs leads to differences in CPS positivity, especially in large TNBC subtype tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.